AR130167A1 - Derivados bicíclicos de tetrahidroazepina - Google Patents
Derivados bicíclicos de tetrahidroazepinaInfo
- Publication number
- AR130167A1 AR130167A1 ARP230102108A ARP230102108A AR130167A1 AR 130167 A1 AR130167 A1 AR 130167A1 AR P230102108 A ARP230102108 A AR P230102108A AR P230102108 A ARP230102108 A AR P230102108A AR 130167 A1 AR130167 A1 AR 130167A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- halo
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en el que: R¹ es heteroarilo de 5 o 6 miembros, en el que R¹ está opcionalmente sustituido con uno o más R¹⁰ que puede ser el mismo o diferente; R² se selecciona de hidrógeno y halógeno; R⁴ se selecciona de fenilo y piridinilo, en el que R⁴ está opcionalmente sustituido con uno o más R¹¹ que puede ser el mismo o diferente; R¹⁰ se selecciona de: vii) alquilo C₁₋₆, opcionalmente sustituido con uno o más halógeno, amino, alcoxi C₁₋₆, -S(O)₂(alquilo C₁₋₆), ciano; viii) cicloalquilo C₃₋₁₀, opcionalmente sustituido con uno o más halógeno, ciano, amino; ix) heterociclilo de 3 - 10 miembros, opcionalmente sustituido con uno o más halógeno, alquilo C₁₋₁₀, amino, halo-alquilo C₁₋₆, hidroxi, ciano, -C(O)O-(R¹⁰q), cicloalquilo C₃₋₁₀, en el que el alquilo C₁₋₁₀ está opcionalmente sustituido con uno o más hidroxi, alcoxi C₁₋₆; x) -N(R¹⁰ᵉR¹⁰ᶠ); xi) heteroarilo, opcionalmente sustituido con uno o más alquilo C₁₋₁₀, halógeno; R¹⁰ᵉ y R¹⁰ᶠ se seleccionan cada uno independientemente de: i) hidrógeno; ii) alquilo C₁₋₆, opcionalmente sustituido con uno o más, ciano, halógeno, hidroxi; iii) cicloalquilo C₃₋₁₀, opcionalmente sustituido con uno o más halógeno, alquilo C₁₋₁₀; R¹⁰q es alquilo C₁₋₅, en el que el alquilo C₁₋₅ está opcionalmente sustituido con uno o más hidroxi; R¹¹ se selecciona de: i) halógeno; ii) alcoxi C₁₋₆, opcionalmente sustituido con uno o más alquilo C₁₋₆, arilo C₅₋₆, cicloalquilo C₃₋₁₀, halo-alquilo C₁₋₆, heterociclilo C₃₋₁₀, en el que el heterociclilo de 3 - 10 miembros está opcionalmente sustituido con alquilo C₁₋₆; iii) heteroarilo de 5 - 6 miembros, opcionalmente sustituido con uno o más halógeno, halo-alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, alquilo C₁₋₆, halo-alcoxi C₁₋₆; iv) fenilo, opcionalmente sustituido con uno o más alcoxi C₁₋₆, halo-alquilo C₁₋₆; v) -O(R¹¹ᵃ); R¹¹ᵃ se selecciona de alquilo C₁₋₆, cicloalquilo C₃₋₆, fenilo y halo-alquilo C₁₋₆. Reivindicación 13: Un proceso para la preparación de un compuesto de fórmula (1) de acuerdo con una cualquiera de las reivindicaciones 1 a 12, o una sal farmacéuticamente aceptable del mismo, que comprende hacer reaccionar un compuesto de fórmula (18) en el que R¹, R² y R⁴ son como se define en una cualquiera de las reivindicaciones 1 a 11 y PG es un grupo protector de amino, con un agente de desprotección adecuado para formar dicho compuesto de fórmula (1). Reivindicación 18: El compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 12, o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento, prevención y/o retardo de la progresión del cáncer. Reivindicación 19: El compuesto para su uso de acuerdo con la reivindicación 18, en el que el cáncer está asociado con una señalización anómala de diacilglicerol cinasa, en el que la diacilglicerol cinasa se selecciona de DGKa y/o DGKz.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22189830 | 2022-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130167A1 true AR130167A1 (es) | 2024-11-13 |
Family
ID=82898753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102108A AR130167A1 (es) | 2022-08-11 | 2023-08-10 | Derivados bicíclicos de tetrahidroazepina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250236614A1 (es) |
| EP (1) | EP4568960A1 (es) |
| JP (1) | JP2025526726A (es) |
| CN (1) | CN119677732A (es) |
| AR (1) | AR130167A1 (es) |
| TW (1) | TW202417001A (es) |
| WO (1) | WO2024033458A1 (es) |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| MX9700535A (es) | 1994-07-21 | 1997-04-30 | Akzo Nobel Nv | Formulaciones de peroxido de cetona ciclico. |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DK0980244T3 (da) | 1997-05-06 | 2003-09-29 | Wyeth Corp | Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CA2306155A1 (en) | 1997-11-06 | 1999-05-20 | Philip Frost | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| BRPI0821962A2 (pt) | 2008-01-03 | 2019-05-07 | Univ De La Mediterrannee Aix Marseille Ii | composições e métodos usados durante um tratamento anti-hiv |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN104470905B (zh) * | 2012-08-09 | 2017-09-12 | 霍夫曼-拉罗奇有限公司 | 取代的杂‑氮杂*酮化合物 |
| WO2016139181A1 (en) | 2015-03-02 | 2016-09-09 | Apeiron Biologics Ag | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases |
-
2023
- 2023-08-10 JP JP2025507468A patent/JP2025526726A/ja active Pending
- 2023-08-10 AR ARP230102108A patent/AR130167A1/es unknown
- 2023-08-10 CN CN202380058731.9A patent/CN119677732A/zh active Pending
- 2023-08-10 WO PCT/EP2023/072129 patent/WO2024033458A1/en not_active Ceased
- 2023-08-10 EP EP23755359.9A patent/EP4568960A1/en active Pending
- 2023-08-10 TW TW112130057A patent/TW202417001A/zh unknown
-
2025
- 2025-02-05 US US19/045,748 patent/US20250236614A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024033458A1 (en) | 2024-02-15 |
| TW202417001A (zh) | 2024-05-01 |
| EP4568960A1 (en) | 2025-06-18 |
| CN119677732A (zh) | 2025-03-21 |
| JP2025526726A (ja) | 2025-08-15 |
| US20250236614A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121044A1 (es) | Inhibidores de egfr | |
| AR113299A1 (es) | Compuestos de isoindolina | |
| AR111524A1 (es) | Compuestos bicíclicos como inhibidores de atx | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR119943A1 (es) | Compuestos heterocíclicos | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR116483A1 (es) | Inhibidores de egfr de quinazolina | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
| AR128440A1 (es) | Inhibidores de cinasas raf | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR120864A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR130167A1 (es) | Derivados bicíclicos de tetrahidroazepina | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR130169A1 (es) | Derivados de tetrahidrotiazepina bicíclicos | |
| AR119378A1 (es) | Formulación de nanopartículas del inhibidor de bcl-2 | |
| AR119340A1 (es) | DERIVADOS DE TIENO[3,2-b]PIRIDIN-2-CARBOXAMIDA COMO MODULADORES DEL RECEPTOR DE NMDA | |
| AR098854A1 (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| AR093763A1 (es) | Antagonistas de ccr3 de arilsulfonamida isotopicamente enriquecidas | |
| AR113799A1 (es) | Derivados de alcoxiamino para tratar dolor y estados relacionados con dolor |